1280 related articles for article (PubMed ID: 12015766)
1. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
[TBL] [Abstract][Full Text] [Related]
5. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
Childs R; Chernoff A; Contentin N; Bahceci E; Schrump D; Leitman S; Read EJ; Tisdale J; Dunbar C; Linehan WM; Young NS; Barrett AJ
N Engl J Med; 2000 Sep; 343(11):750-8. PubMed ID: 10984562
[TBL] [Abstract][Full Text] [Related]
6. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
[TBL] [Abstract][Full Text] [Related]
7. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
8. Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
Castagna L; Bertuzzi A; Nozza A; Siracusano L; Balzarotti M; Magagnoli M; Sarina B; Timofeeva I; Sinnone M; Grimoldi MG; Farè M; Santoro A
Bone Marrow Transplant; 2002 Aug; 30(4):207-14. PubMed ID: 12203136
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
Al-Zahrani H; Nassar A; Al-Mohareb F; Al-Sharif F; Mohamed S; Al-Anazi K; Patel M; Rasheed W; Saleh AJ; Bakr M; Ahmed S; Ibrahim K; Hussain F; Elkum N; Elhassan T; Nurgat Z; Chaudhri N; Aljurf M
Biol Blood Marrow Transplant; 2011 May; 17(5):717-22. PubMed ID: 20736079
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
12. Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan.
Niiya H; Kanda Y; Saito T; Ohnishi T; Kanai S; Kawano Y; Kamijo K; Iizuka A; Yakushijin K; Ueda K; Chizuka A; Iijima K; Ohnishi M; Nakai K; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Haematologica; 2001 Oct; 86(10):1071-4. PubMed ID: 11602413
[TBL] [Abstract][Full Text] [Related]
13. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
14. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
15. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
[TBL] [Abstract][Full Text] [Related]
17. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.
Wäsch R; Reisser S; Hahn J; Bertz H; Engelhardt M; Kunzmann R; Veelken H; Holler E; Finke J
Bone Marrow Transplant; 2000 Aug; 26(3):243-50. PubMed ID: 10967561
[TBL] [Abstract][Full Text] [Related]
18. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
Chan GW; Gorgun G; Miller KB; Foss FM
Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experience.
Rzepecki P; Zolnierek J; Sarosiek T; Langiewicz P; Szczylik C
Neoplasma; 2005; 52(3):238-42. PubMed ID: 15875086
[TBL] [Abstract][Full Text] [Related]
20. [Reduced intensity of BuCy conditioning regimen for transplantation in the treatment of malignant hematologic diseases].
Chen H; Lu DP; Huang XJ; Liu KY; Xu LP; Han W; Ren HY; Chen YH; Liu DH; Lu J; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):273-6. PubMed ID: 15949287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]